These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 27813474

  • 1. [Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives].
    Bedioune I, Bobin P, Karam S, Lindner M, Mika D, Lechêne P, Leroy J, Fischmeister R, Vandecasteele G.
    Biol Aujourdhui; 2016; 210(3):127-138. PubMed ID: 27813474
    [Abstract] [Full Text] [Related]

  • 2. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
    Bobin P, Belacel-Ouari M, Bedioune I, Zhang L, Leroy J, Leblais V, Fischmeister R, Vandecasteele G.
    Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
    [Abstract] [Full Text] [Related]

  • 3. [Cyclic nucleotide phosphodiesterases: therapeutic targets in cardiac hypertrophy and failure].
    Barthou A, Kamel R, Leroy J, Vandecasteele G, Fischmeister R.
    Med Sci (Paris); 2024; 40(6-7):534-543. PubMed ID: 38986098
    [Abstract] [Full Text] [Related]

  • 4. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.
    Kamel R, Leroy J, Vandecasteele G, Fischmeister R.
    Nat Rev Cardiol; 2023 Feb; 20(2):90-108. PubMed ID: 36050457
    [Abstract] [Full Text] [Related]

  • 5. Regulation of murine cardiac function by phosphodiesterases type 3 and 4.
    Beca S, Aschars-Sobbi R, Panama BK, Backx PH.
    Curr Opin Pharmacol; 2011 Dec; 11(6):714-9. PubMed ID: 22047792
    [Abstract] [Full Text] [Related]

  • 6. Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.
    Kim GE, Kass DA.
    Handb Exp Pharmacol; 2017 Dec; 243():249-269. PubMed ID: 27787716
    [Abstract] [Full Text] [Related]

  • 7. Phosphodiesterase inhibitors.
    Boswell-Smith V, Spina D, Page CP.
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
    Stehlik J, Movsesian MA.
    Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
    [Abstract] [Full Text] [Related]

  • 9. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M, Pekkinen M, Huttunen M, Lamberg-Allardt C.
    Cell Mol Biol Lett; 2005 Jul; 10(2):305-19. PubMed ID: 16010295
    [Abstract] [Full Text] [Related]

  • 10. PDE2 at the crossway between cAMP and cGMP signalling in the heart.
    Weber S, Zeller M, Guan K, Wunder F, Wagner M, El-Armouche A.
    Cell Signal; 2017 Oct; 38():76-84. PubMed ID: 28668721
    [Abstract] [Full Text] [Related]

  • 11. [Role of cyclic nucleotide phosphodiesterases in the cAMP compartmentation in cardiac cells].
    Mika D, Leroy J, Vandecasteele G, Fischmeister R.
    Biol Aujourdhui; 2012 Oct; 206(1):11-24. PubMed ID: 22463992
    [Abstract] [Full Text] [Related]

  • 12. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
    Santos-Silva AJ, Cairrão E, Morgado M, Alvarez E, Verde I.
    Eur J Pharmacol; 2008 Mar 17; 582(1-3):102-9. PubMed ID: 18234184
    [Abstract] [Full Text] [Related]

  • 13. Phosphodiesterase inhibition in heart failure.
    Movsesian M, Stehlik J, Vandeput F, Bristow MR.
    Heart Fail Rev; 2009 Dec 17; 14(4):255-63. PubMed ID: 19096931
    [Abstract] [Full Text] [Related]

  • 14. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
    Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC.
    J Am Soc Nephrol; 2006 Oct 17; 17(10):2742-7. PubMed ID: 16928803
    [Abstract] [Full Text] [Related]

  • 15. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K, Kass DA.
    Annu Rev Pharmacol Toxicol; 2017 Jan 06; 57():455-479. PubMed ID: 27732797
    [Abstract] [Full Text] [Related]

  • 16. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):110-7. PubMed ID: 16458289
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J, Grande JP.
    Exp Biol Med (Maywood); 2007 Jan 08; 232(1):38-51. PubMed ID: 17202584
    [Abstract] [Full Text] [Related]

  • 20. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
    Preedy MEJ.
    Cardiovasc Drugs Ther; 2020 Jun 08; 34(3):401-417. PubMed ID: 32172427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.